Navigation Links
FDA Approves Victrelis for Hepatitis C
Date:5/13/2011

SILVER SPRING, Md., May 13, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment. Victrelis is approved for use in combination with peginterferon alfa and ribavirin.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The safety and effectiveness of Victrelis was evaluated in two phase 3 clinical trials with 1,500 adult patients. In both trials, two-thirds of patients receiving Victrelis in combination with pegylated interferon and ribavirin experienced a significantly increased sustained virologic response (i.e., the hepatitis C virus was no longer detected in the blood 24 weeks after stopping treatment), compared to pegylated interferon and ribavirin alone, the current standard of care.

When a person sustains a virologic response after completing treatment, this suggests that HCV infection has been cured.

Sustained virologic response can result in decreased cirrhosis and complications of liver disease, decreased rates of liver cancer (hepatocelluar carcinoma), and decreased mortality.

"Victrelis is an important new advance for patients with hepatitis C," said Edward Cox, M.D., M.P.H, director, Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. "This new medication provides an effective treatment for a serious disease, and offers a greater chance of cure for some patients' hepatitis C infection compared to currently available therapy."

According to the U.S. Centers for Disease Control and Prevention, about 3.2 million people in the United States have chronic hepatitis C, a viral disease that causes inflammation of the liver tha
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves New Treatment for Rare Type of Pancreatic Cancer
2. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
3. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
4. FDA Approves New Treatment for Type 2 Diabetes
5. FDA Approves Zytiga for Late-Stage Prostate Cancer
6. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
7. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
8. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
9. FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis
10. FDA Approves New Medical Device for Form of Brain Cancer
11. FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... , Aug. 20, 2014 Trovagene, Inc. (NASDAQ: ... today that results from two clinical studies will be ... the Company,s urine-based diagnostic test for the detection of ... conference is scheduled to take place in ... 25 th . Additionally, a new U.S. patent was ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
(Date:8/20/2014)... PA (PRWEB) August 20, 2014 A ... products from the blood did not improve survival chances ... analysis led by experts at the University of ... published online today in the journal PLOS One ... standardly used for people with sudden kidney failure, may ...
(Date:8/20/2014)... Steven Reinberg HealthDay Reporter ... disorder that dismantles a baby,s immune system is twice as ... 3 million infants says. This is the first evaluation ... treatable condition known as severe combined immunodeficiency (SCID), or "Bubble ... of this condition by the boy in the bubble, who ...
(Date:8/20/2014)... Caddis Partners LLC, has built one of the most ... in recent years, developing or acquiring 2 million square ... more than $100 million last year alone. , In ... geographic regions and a wider array of product types ... an enhanced brand identity that includes a new logo, ...
(Date:8/20/2014)... 20, 2014 Understanding the impact ... physician stakeholders networks impacting the launch of new ... Canada, and Emerging Markets. , This Flash Report ... on stakeholder management needs for the melanoma market. ... targeted therapy investigational agents that are further improving ...
(Date:8/20/2014)... MI (PRWEB) August 20, 2014 In its ... drug and alcohol treatment program that gets clients off to ... recovery they can believe in, is highlighting an important and ... be heeded by everyone who wants to understand the insidious ... are of the belief that drug abuse targets a certain ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3
... Systems Operations, Security and, Maintenance ... ARLINGTON, Va., Oct. 16 Vangent, ... and business process outsourcing,solutions, today announced it ... Information and Decision Support (EIDS) Infrastructure,Operations, Security ...
... risk of asthma than their urban counterparts or even ... a University of Alberta study. , Analysis of ... 12 years in the ongoing Canadian National Longitudinal Survey ... in a farming environment had a lower risk of ...
... COLUMBUS, Ga., Oct. 16 Aflac Incorporated,(NYSE: AFL ... financial,results after the market closes on October 23, 2007. ... will,webcast a conference call scheduled for 9:30 a.m. (EDT) ... and CEO Dan,Amos will discuss third quarter results and ...
... STA Travel, the world,s largest student,and youth travel organization, and ... pandemic in Africa. Through the "Good Cents,Initiative", college students across ... to compose a song, direct a video or write an,essay ... where they,will work side by side with Keep A Child ...
... "I would have never,guessed that some of the best ... come from Planned Parenthood, the largest,abortion chain in the ... Days for Life., "People in more than 80 ... about half of the vigils are being conducted outside ...
... is commonly thought that men with low IQs sexually ... deviance, new research has found the men may sexually ... previously taken. , A team of North American ... an intellectual disability and a history of sexual offence ...
Cached Medicine News:Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:Farm kids have lower risk of asthma, study shows 2Health News:Aflac Incorporated to Release Third Quarter Results On October 23, 2007 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 3Health News:40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode 2Health News:'Corrective' sex education may make sexual offenders more dangerous 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: